Table 2. Univariate and multivariate analysis of prognostic factors for overall, myelofibrosis and leukemia-free survivals in patients with polycythemia vera (n=262).
| Variables |
Overall survival |
Myelofibrosis-free survival |
Leukemia-free survival |
|||
|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |
| BM reticulin fibrosis⩾grade 1 | P=0.5 | P=0.009 HR 2.9; 95% CI 1.32–6.78 | P=0.02 HR 3.3; 95% CI 1.24–8.60 | P=0.2 | NA | |
| Age | P<0.0001 | P=0.4 | P=0.7 | NA | ||
| Sex | P=0.2 | P=0.6 | P=0.6 | NA | ||
| Age>60 years | P<0.0001 HR 5.1; 95% CI 3.25–8.07 | P<0.0001 HR 6.1; 95% CI 2.66–13.96 | P=0.4 | P=0.8 | NA | |
| Hemoglobin, g/dl | P=0.6 | P=0.3 | P=0.6 | NA | ||
| Platelets, × 109/l | P=0.2 | P=0.8 | P=0.08 | NA | ||
| WBC × 109/l | P=0.0002 | P=0.1 | P=0.9 | NA | ||
| WBC⩾11 × 109/l | P=0.03 HR 1.6; 95% CI 1.05–2.34 | P=0.4 | P=0.7 | NA | ||
| WBC⩾15 × 109/l | P=0.0001 HR 2.2; 95% CI 1.48–3.41 | P=0.001 HR 3.3; 95% CI 1.60–6.93 | P=0.02 HR 2.8; 95% CI 1.17–6.48 | P=0.04 HR 2.8; 95% CI 1.02–7.62 | P=0.2 | NA |
| Palpable splenomegaly at diagnosis | P=0.1 | P=0.02 HR 2.6; 95% CI 1.14–6.08 | P=0.04 HR 2.4; 95% CI 1.02–5.8 | P=0.03 HR 11.4; 95% CI 1.27–101.90 | NA | |
| Presence of pruritus | P=0.6 | P=0.09 | P=0.3 | NA | ||
| Presence of erythromelagia | P=0.8 | P=0.8 | P=0.2 | NA | ||
| Thrombosis history | P=0.005 HR 1.8; 95% CI 1.19–2.71 | P=0.2 | P=0.5 | NA | ||
| Thrombotic events after diagnosis | P=0.9 | P=0.7 | NA | NA | ||
| JAK2 | P=0.47 | P=0.6 | NA | |||
| TET2 | P=0.2 | P=0.8 | NA | |||
| ASXL1 | P=0.006 HR 3.6; 95% CI 1.43–8.97 | P=0.0006 HR 5.4; 95% CI 2.05–14.06 | P=0.4 | P=0.1 | NA | |
Abbreviations: BM, bone marrow; CI, confidence interval; HR, hazard ratio; NA, not applicable; WBC, white blood cell count. Bold font indicates significant P-values.